Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader By James Waldron Mar 11, 2025 10:06am Pfizer Arvinas breast cancer PROTAC ...

ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the ...

The PROTAC candidates “… demonstrate potent antiretroviral activity in HIV-infected primary cells, supporting further development for testing in the context of HIV-1 reservoir reduction in ...

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system.In this phase 3, open-label, randomized ...

PROTAC technology offers hope for treating castration-resistant prostate cancer. Download PDF Copy; Reviewed. Compuscript Ltd Jan 30 2025. Announcing a new publication for Acta Materia Medica journal.

This PROTAC vaccine technology could also be useful for generating live-attenuated vaccines against other types of pathogens." Prof. Si Longlong from the Shenzhen Institute of Advanced Technology ...

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, ... bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy.